Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-34012476

RESUMEN

Lead is one of the most common environmental contaminants in the Earth's crust, which induces a wide range of humans biochemical changes. Previous studies showed that Opuntia dillenii (OD) fruit possesses several antioxidant and anti-inflammatory properties. The present study evaluates OD fruit hydroalcoholic extract (OHAE) hepatoprotective effects against lead acetate- (Pb-) induced toxicity in both animal and cellular models. Male rats were grouped as follows: control, Pb (25 mg/kg/d i.p.), and groups 3 and 4 received OHAE at 100 and 200 mg/kg/d + Pb (25 mg/kg/d i.p.), for ten days of the experiment. Thereafter, we evaluated the levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), catalase (CAT) activity and malondialdehyde (MDA) in serum, and liver histopathology. Additionally, the cell study was also done using the HepG2 cell line for measuring the direct effects of the extract on cell viability, oxidative stress MDA, and glutathione (GSH) and inflammation tumor necrosis factor-α (TNF-α) following the Pb-induced cytotoxicity. Pb significantly increased the serum levels of ALT, AST, ALP, and MDA and liver histopathological scores but notably decreased CAT activity compared to the control group (p < 0.001 for all cases). OHAE (100 and 200 mg/kg) significantly reduced the levels of serum liver enzyme activities and MDA as well as histopathological scores while it significantly increased CAT activity compared to the Pb group (p < 0.001-0.05 for all cases). OHAE (20, 40, and 80 µg/ml) concentration dependently and significantly reduced the levels of MDA and TNF-α, while it increased the levels of GSH and cell viability in comparison to the Pb group (p < 0.001-0.05 for all cases). These data suggest that OHAE may have hepatoprotective effects against Pb-induced liver toxicity both in vitro and in vivo by its antioxidant and anti-inflammatory activities.

2.
Environ Sci Pollut Res Int ; 25(5): 4896-4903, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29204934

RESUMEN

The kidney is one of the main organs affected by lead toxicity. We investigated the effects of berberine on lead-induced nephrotoxicity in adult male Wistar rats. Animals received an aqueous solution of lead acetate (500 mg Pb/L in the drinking water) and/or berberine (50 mg/kg, i.g.) for 8 weeks. Lead caused an increase in malondialdehyde (P < 0.001) and total oxidant status (P < 0.01), and a decrease in reduced glutathione (P < 0.001), catalase (P < 0.01), superoxide dismutase (P < 0.001), and total antioxidant capacity (P < 0.05). Berberine prevented the prooxidant and antioxidant imbalance induced by lead (P < 0.001). Berberine corrected the increased relative kidney weight (P < 0.05) and biomarkers of renal function (creatinine (P < 0.001), urea (P < 0.05), uric acid (P < 0.001), albumin (P < 0.01), and total protein (P < 0.05)) in lead group. It also attenuated lead-induced abnormal renal structure. The results confirmed renoprotective effects of berberine in an animal model of lead-induced nephrotoxicity by molecular, biochemical, and histopathological analysis through inhibiting lipid peroxidation and enhancing antioxidant defense system mechanisms. Therefore, berberine makes a good candidate to protect against the deleterious effect of chronic lead intoxication.


Asunto(s)
Berberina/uso terapéutico , Riñón/efectos de los fármacos , Plomo/toxicidad , Sustancias Protectoras/uso terapéutico , Animales , Antioxidantes/metabolismo , Biomarcadores/metabolismo , Catalasa/metabolismo , Creatinina/metabolismo , Glutatión/metabolismo , Riñón/metabolismo , Masculino , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo
3.
Nutr Neurosci ; 20(9): 547-554, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27367870

RESUMEN

OBJECTIVES: Ethanol consumption induces neurological disorders including cognitive dysfunction. Oxidative damage is considered a likely cause of cognitive deficits. We aimed to investigate the effects of rosmarinic acid (RA) in different doses for 30 days on chronic ethanol-induced cognitive dysfunction using the passive avoidance learning (PAL) and memory task in comparison with donepezil, a reference drug. We also evaluated the levels of superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation in hippocampus as possible mechanisms. METHODS: Memory impairment was induced by 15% w/v ethanol (2 g/kg, i.g.) administration for 30 days. RA (8, 16, and 32 mg/kg, i.g.) or donepezil (2 mg/kg, i.g.) was administered 30 minutes before ethanol. The acquisition trial was done 1 hour after the last administration of RA and donepezil. At the end, animals were weighed and hippocami were isolated for analyzing of oxidant/antioxidant markers. RESULTS: Ethanol caused cognition deficits in the PAL and memory task. While RA 16 and 32 mg/kg improved cognition in control rats, it prevented learning and memory deficits of alcoholic groups. RA 8 mg/kg did not influence cognitive function in both control and alcoholic rats. RA 32 mg/kg had comparable effects with donepezil in prevention of acquisition and retention memory impairment. The higher doses of RA not only prevented increased lipid peroxidation and nitrite content but also decreased SOD, CAT, GSH, and FRAP levels in alcoholic groups and exerted antioxidant effects in non-alcoholic rats. DISCUSSION: We showed that RA administration dose-dependently prevented cognitive impairment induced by chronic ethanol in PAL and memory and disturbed oxidant/antioxidant status as a possible mechanism. The antioxidant, anticholinesterase, and neuroprotective properties of RA may be involved in the observed effects. Therefore, RA represents a potential therapeutic option against chronic ethanol-induced amnesia which deserves consideration and further examination.


Asunto(s)
Trastornos del Sistema Nervioso Inducidos por Alcohol/prevención & control , Antioxidantes/uso terapéutico , Cinamatos/uso terapéutico , Depsidos/uso terapéutico , Suplementos Dietéticos , Discapacidades para el Aprendizaje/prevención & control , Trastornos de la Memoria/prevención & control , Nootrópicos/uso terapéutico , Trastornos del Sistema Nervioso Inducidos por Alcohol/metabolismo , Trastornos del Sistema Nervioso Inducidos por Alcohol/patología , Trastornos del Sistema Nervioso Inducidos por Alcohol/fisiopatología , Animales , Antioxidantes/administración & dosificación , Reacción de Prevención/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Biomarcadores/metabolismo , Inhibidores de la Colinesterasa/administración & dosificación , Inhibidores de la Colinesterasa/uso terapéutico , Cinamatos/administración & dosificación , Depsidos/administración & dosificación , Donepezilo , Conducta Exploratoria/efectos de los fármacos , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Hipocampo/patología , Indanos/uso terapéutico , Discapacidades para el Aprendizaje/etiología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Trastornos de la Memoria/etiología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/uso terapéutico , Nootrópicos/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Piperidinas/uso terapéutico , Distribución Aleatoria , Ratas Wistar , Ácido Rosmarínico
4.
Neurosci Lett ; 622: 72-7, 2016 05 27.
Artículo en Inglés | MEDLINE | ID: mdl-27113201

RESUMEN

Learning and memory impairment occurs in diabetes. Salvia officinalis L. (SO) has been used in Iranian traditional medicine as a remedy against diabetes. We hypothesized that chronic administration of SO (400, 600 and 800mg/kg, p.o.) and its principal constituent, rosmarinic acid, would affect on passive avoidance learning (PAL) and memory in streptozocin-induced diabetic and non-diabetic rats. We also explored hypoglycemic and antioxidant activities of SO as the possible mechanisms. Treatments were begun at the onset of hyperglycemia. PAL was assessed 30days later. Retention test was done 24h after training. At the end, animals were weighed and blood samples were drawn for further analyzing of glucose and oxidant/antioxidant markers. Diabetes induced deficits in acquisition and retrieval processes. SO (600 and 800mg/kg) and rosmarinic acid reversed learning and memory deficits induced by diabetes and improved cognition of healthy rats. While the dose of 400mg/kg had no effect, the higher doses and rosmarinic acid inhibited hyperglycemia and lipid peroxidation as well as enhanced the activity of antioxidant enzymes superoxide dismutase and catalase. SO prevented diabetes-induced acquisition and memory deficits through inhibiting hyperglycemia, lipid peroxidation as well as enhancing antioxidant defense systems. Therefore, SO and its principal constituent rosmarinic acid represent a potential therapeutic option against diabetic memory impairment which deserves consideration and further examination.


Asunto(s)
Antioxidantes/farmacología , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/farmacología , Discapacidades para el Aprendizaje/tratamiento farmacológico , Trastornos de la Memoria/tratamiento farmacológico , Extractos Vegetales/farmacología , Salvia officinalis/química , Animales , Antioxidantes/uso terapéutico , Reacción de Prevención/efectos de los fármacos , Cinamatos/farmacología , Depsidos/farmacología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/psicología , Hipoglucemiantes/uso terapéutico , Discapacidades para el Aprendizaje/psicología , Masculino , Memoria/efectos de los fármacos , Trastornos de la Memoria/psicología , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Ratas Wistar , Retención en Psicología/efectos de los fármacos , Ácido Rosmarínico
5.
Am J Drug Alcohol Abuse ; 41(5): 405-13, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26337199

RESUMEN

BACKGROUND: Salvia officinalis L. (SO) has effects on the central nervous system, including anti-addiction properties that may involve an opioid mechanism. OBJECTIVE: Effects of a hydroalcoholic extract of SO on nociception and on morphine-induced tolerance and dependence were evaluated in rats. METHODS: Tolerance and dependence were induced by injection of morphine (10 mg/kg, s.c.) or escalating doses of morphine (2.5, 2.5, 5, 10, 20, 40 and 50 mg/kg, s.c.) twice daily for 7 days. SO (400, 600 and 800 mg/kg, i.g.) was administered before morphine. The tail-flick and naloxone precipitation withdrawal tests were used to evaluate tolerance and dependence. Sedative effects as well as total polyphenolic and flavonoid were also measured. RESULTS: The morphine-treated group showed significant decrements in the percentage maximum possible effect (%MPE) on days 5 and 7 compared to the first day, illustrating morphine tolerance. Higher doses decreased morphine tolerance. Furthermore, SO (600 and 800 mg/kg) attenuated almost all of the withdrawal signs including weight loss, jumping, penis licking, teeth chattering, wet dog shakes, rearing, standing, sniffing, face grooming and paw tremor and increased sleep duration (64.5 ± 9.7, 100.3 ± 4.7, respectively). Total polyphenolic and flavonoid content of SO was 138 and 69 mg per g of dried extract, respectively. CONCLUSION: SO has antinociceptive effects and may decrease tolerance and dependence induced by repeated morphine administration. However, to determine whether treatment with SO blocks tolerance by interfering with neurobiological mechanisms that mediate the development of morphine tolerance will require further studies.


Asunto(s)
Analgésicos/farmacología , Tolerancia a Medicamentos , Hipnóticos y Sedantes/farmacología , Dependencia de Morfina/prevención & control , Morfina/farmacología , Extractos Vegetales/farmacología , Salvia officinalis/química , Analgésicos Opioides/farmacología , Animales , Relación Dosis-Respuesta a Droga , Hipnóticos y Sedantes/química , Masculino , Extractos Vegetales/química , Hojas de la Planta/química , Ratas , Síndrome de Abstinencia a Sustancias/prevención & control
6.
Med Princ Pract ; 24(1): 47-52, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25402675

RESUMEN

OBJECTIVE: The efficacy of oral administration of Melissa officinalis essential oil (MOEO) on hyperalgesia was investigated using the formalin test in streptozotocin (STZ)-induced diabetic rats. MATERIALS AND METHODS: Animals were divided into control, MOEO-treated control (0.01, 0.02 and 0.04 mg/day), diabetic and MOEO-treated diabetic (0.01, 0.02 and 0.04 mg/day) groups. Nociceptive testing was performed on male adult Wistar rats 4 weeks after the onset of hyperglycemia. At the end of the experiment, all rats were weighed and plasma glucose measurements were performed. RESULTS: Diabetes was associated with significant hyperalgesia during both phases of the formalin test. MOEO (0.04 mg/day) completely reversed hyperalgesia in diabetic rats, while MOEO (0.02 and 0.04 mg/day) caused less intensive nociceptive behaviors during both phases of the test in control rats. MOEO at both high doses restored euglycemia and reduced the body weight of treated diabetic animals compared to untreated diabetic animals. The 0.01-mg dose of MOEO did not alter pain responses in the control or diabetic groups compared to their respective controls. CONCLUSIONS: This study shows that chronic administration of MOEO displays efficacy in an experimental model of diabetic hyperalgesia. MOEO may therefore show promise as a treatment for painful diabetic neuropathy.


Asunto(s)
Analgésicos/administración & dosificación , Neuropatías Diabéticas/tratamiento farmacológico , Melissa , Aceites Volátiles/farmacología , Fitoterapia , Administración Oral , Animales , Diabetes Mellitus , Modelos Animales de Enfermedad , Hipoglucemiantes/farmacología , Masculino , Aceites Volátiles/administración & dosificación , Dimensión del Dolor , Ratas , Ratas Wistar , Estreptozocina
7.
J Physiol Biochem ; 70(4): 997-1006, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25407136

RESUMEN

Hyperalgesia and allodynia are among the common manifestations of painful diabetic neuropathy. Naringenin (NA) has some biological activities, including anti-inflammatory, analgesic, and antidiabetic effects. We investigated the effects of NA administration at different doses, 20, 50, and 100 mg/kg, on streptozotocin (STZ)-induced hyperalgesia and allodynia in rats. The animals received saline or NA (20, 50, and 100 mg/kg, p.o.; once daily) for 8 weeks. Hyperalgesia was assessed by tail flick (TF) and formalin tests. Von Frey filaments were used for tactile allodynia evaluation. At the end, all rats were weighed and underwent plasma glucose and superoxide dismutase measurement. Diabetes caused significant hyperalgesia and allodynia during the above tests. NA 50 and 100 mg/kg reversed chemical and thermal hyperalgesia in diabetic rats. There were no significant differences in pain responses between NA (50 and 100 mg/kg)-treated diabetic rats and pregabalin-treated diabetic animals. Administration of NA 20 mg/kg did not alter pain-related behaviors in control and diabetic groups compared to the respective control ones. NA 50 and 100 mg/kg restored hyperglycemia as well as the decreased levels of (superoxide dismutase) SOD activity in diabetic rats. The body weight of treated diabetic rats increased significantly compared to untreated diabetics. Prolonged oral administration of NA (50 and 100 mg/kg) ameliorated some aspects of diabetic neuropathy by causing hypoglycemia and increasing the levels of antioxidant enzyme SOD. Therefore, NA makes a good candidate for treatment of diabetic neuropathy in clinical studies.


Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Flavanonas/administración & dosificación , Hiperalgesia/prevención & control , Hipoglucemiantes/administración & dosificación , Administración Oral , Animales , Glucemia , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Hiperalgesia/sangre , Hiperalgesia/etiología , Masculino , Ratas Wistar , Superóxido Dismutasa/sangre
8.
Eur J Pharmacol ; 742: 113-7, 2014 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-25220244

RESUMEN

Pregabalin is recently proposed as analgesic or adjuvant in pain management. While previous preclinical investigations have evaluated pregabalin-opioid interactions, the effect of pregabalin on opioid tolerance and dependency has not yet been studied. Here we evaluated the effects of different doses of pregabalin (50, 100 and 200mg/kg, s.c.) on morphine-induced tolerance and dependency in rats. Adult male Wistar rats were rendered tolerant to analgesic effect of morphine by injection of morphine (10mg/kg, s.c.) twice daily for 7 days. To develop morphine dependence, rats were given escalating doses of morphine. To determine the effect of pregabalin on the development of morphine tolerance and dependence, different doses of pregabalin were administrated before morphine. The tail-flick and naloxone precipitation withdrawal tests were used to evaluate the degree of tolerance and dependence, respectively. Chronic morphine-injected rats showed significant decrements in the percentage maximum possible effect (%MPE) of morphine on the days 5 and 7 (32.5%±3.5, 21.5%±4, respectively) compared to the first day (100%) which showed morphine tolerance. Pregabalin 200mg/kg completely prevented the development of morphine tolerance. In addition, concomitant treatment of morphine with pregabalin attenuated almost all of the naloxone-induced withdrawal signs which include weight loss, jumping, penis licking, teeth chattering, wet dog shakes, rearing, standing, sniffing, face grooming and paw tremor. These data show that pregabaline has a potential anti-tolerant/anti-dependence property against chronic usage of morphine. Therefore, pregabalin appears to be a promising candidate for the treatment of opioid addiction after confirming by future clinical studies.


Asunto(s)
Analgésicos Opioides/farmacología , Tolerancia a Medicamentos/fisiología , Dependencia de Morfina/tratamiento farmacológico , Morfina/farmacología , Ácido gamma-Aminobutírico/análogos & derivados , Analgésicos Opioides/administración & dosificación , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Masculino , Morfina/administración & dosificación , Dependencia de Morfina/fisiopatología , Dimensión del Dolor/efectos de los fármacos , Pregabalina , Ratas , Ratas Wistar , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/fisiopatología , Ácido gamma-Aminobutírico/farmacología
9.
Med Sci Monit ; 18(1): BR41-46, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22207108

RESUMEN

BACKGROUND: Cognitive impairment occurs in diabetes mellitus. Teucrium polium L. (Lamiaceae) has been used in folk medicine to improve mental performance. Here we hypothesized that chronic treatment with an aqueous extract of Teucrium polium (100, 200 and 400 mg/kg, p.o.) would have an effect on passive avoidance learning (PAL) and memory in control and streptozocin-induced diabetic rats. MATERIAL/METHODS: Treatments were begun at the onset of hyperglycemia, and PAL was assessed 30 days later. A retention test was performed 24 h (hours) after training. After PAL and memory assessment, animals were weighed and blood samples were drawn for plasma glucose measurement. RESULTS: Diabetes caused impairment in acquisition of PAL and retrieval of memory. Teucrium polium treatment (200 and 400 mg/kg) improved learning and memory in control rats and reversed learning and memory deficits in diabetic rats. The 100 mg/kg dose did not affect cognitive function. Teucrium polium treatment partially improved the reduced body weight and hyperglycemia of treated diabetic rats, although the differences were not significant compared to non-treated diabetic rats. CONCLUSIONS: These results show that Teucrium polium prevented the deleterious effects of diabetes on PAL and memory. Antioxidant, anticholinesterase and hypoglycemic effects of Teucrium may be involved in the obtained effects. Therefore, Teucrium polium appears to be a promising candidate for memory improvement in diabetes, but this needs confirmation by future clinical studies.


Asunto(s)
Reacción de Prevención/efectos de los fármacos , Diabetes Mellitus Experimental/complicaciones , Discapacidades para el Aprendizaje/prevención & control , Trastornos de la Memoria/prevención & control , Extractos Vegetales/farmacología , Análisis de Varianza , Animales , Antioxidantes/farmacología , Glucemia/metabolismo , Inhibidores de la Colinesterasa/farmacología , Hipoglucemiantes/farmacología , Discapacidades para el Aprendizaje/etiología , Trastornos de la Memoria/etiología , Extractos Vegetales/uso terapéutico , Ratas , Teucrium
10.
Acta Physiol Hung ; 98(2): 221-30, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21616781

RESUMEN

Cognitive impairment occurs in diabetes mellitus. Glabridin as a major active flavonoids in Glycyrrhiza glabra (licorice) improves learning and memory in mice. In the present study, we investigated the effect of chronic treatment with glabridin (5, 25 and 50 mg/kg, p.o.) on cognitive function in control and streptozotocin (STZ)-induced diabetic rats.Animals were divided into untreated control, glabridin-treated control (5, 25 and 50 mg/kg), untreated diabetic and glabridin treated diabetic (5, 25 and 50 mg/kg) groups. Treatments were begun at the onset of hyperglycemia. Passive avoidance learning (PAL) and memory was assessed 30 days later. Diabetes caused cognition deficits in the PAL and memory paradigm. While oral glabridin administration (25 and 50 mg/kg) improved learning and memory in non-diabetic rats, it reversed learning and memory deficits of diabetic rats. Low dose glabridin (5 mg/kg) did not alter cognitive function in non-diabetic and diabetic groups. Glabridin treatment partially improved the reduced body weight and hyperglycemia of diabetic rats although the differences were not significant. The combination of antioxidant, neuroprotective and anticholinesterase properties of glabridin may all be responsible for the observed effects. These results show that glabridin prevented the deleterious effects of diabetes on learning and memory in rats. Further studies are warranted for clinical use of glabridin in the management of demented diabetic patients.


Asunto(s)
Diabetes Mellitus Experimental/psicología , Glycyrrhiza/metabolismo , Isoflavonas/metabolismo , Isoflavonas/uso terapéutico , Discapacidades para el Aprendizaje/prevención & control , Trastornos de la Memoria/prevención & control , Fenoles/metabolismo , Fenoles/uso terapéutico , Extractos Vegetales/uso terapéutico , Animales , Glucemia/fisiología , Peso Corporal/fisiología , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/fisiopatología , Trastornos del Conocimiento/prevención & control , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/complicaciones , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Discapacidades para el Aprendizaje/etiología , Discapacidades para el Aprendizaje/fisiopatología , Masculino , Trastornos de la Memoria/etiología , Trastornos de la Memoria/fisiopatología , Ratas , Ratas Wistar , Estreptozocina
11.
Phytother Res ; 25(4): 544-9, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20836158

RESUMEN

Cognitive impairment occurs in diabetes mellitus. Hypericum perforatum has been used in folk medicine to improve mental performance. Here it is hypothesized that chronic treatment with an extract of Hypericum perforatum (6, 12 and 25 mg/kg, p.o.) would have effects on passive avoidance learning (PAL) and memory in control and streptozotocin-induced diabetic rats. Treatments were begun at the onset of hyperglycaemia. PAL was assessed 30 days later. A retention test was done 24 h after training. At the end, the animals were weighed and blood samples were drawn for plasma glucose measurement. Diabetes caused impairment in acquisition and retrieval processes of PAL and memory. Hypericum treatment (12 and 25 mg/kg) improved learning and memory in control rats and reversed learning and memory deficits in diabetic rats. A dose of 6 mg/kg did not affect cognitive function. Hypericum administration did not alter the body weight and plasma glucose levels. Antioxidant properties and cholinergic facilitatory effects of Hypericum may be involved in its nootropic effects. These results show that Hypericum perforatum prevented the deleterious effects of diabetes on PAL and memory. As Hypericum would be free of major side effects compared with other nootropic medications, it may provide a new potential alternative for demented diabetic patients.


Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Hypericum/química , Discapacidades para el Aprendizaje/tratamiento farmacológico , Trastornos de la Memoria/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Animales , Glucemia/análisis , Relación Dosis-Respuesta a Droga , Discapacidades para el Aprendizaje/complicaciones , Trastornos de la Memoria/complicaciones , Ratas , Estreptozocina
12.
Diabetes Res Clin Pract ; 73(1): 17-22, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16417942

RESUMEN

BACKGROUND: Peripheral neuropathy is a common complication of diabetes mellitus. It has been shown that hyperglycemia may contribute to its development but the exact pathophysiology underlying this complication is not fully understood. Since oral magnesium supplementation can normalize hyperglycemia induced by diabetes in rats, this study was designed to examine the effect of oral magnesium administration on thermal hyperalgesia in streptozocin-induced diabetic rats. MATERIAL AND METHODS: Twenty-four male adult wistar rats were divided equally into control, magnesium-treated control, diabetic and magnesium-treated diabetic groups. In magnesium-treated diabetic rats, magnesium sulfate (10g/l) was added into the drinking water once diabetes was established (10 days after STZ injection) and continued for 8 weeks. Mg-treated control animals received magnesium sulfate in the same dose and over the same time period. The other two groups; control and diabetic animals, only received tap water. At the end of the 8 weeks, thermal pain threshold was assessed by tail flick test and magnesium and glucose plasma levels were measured in all groups. RESULT: A significant decrease (p<0.001) in thermal pain threshold and plasma magnesium levels and an increase in plasma glucose levels (p<0.001) were seen in diabetic rats 8 weeks after diabetes induction. After 8 weeks of oral magnesium, thermal hyperalgesia was normalized and plasma magnesium and glucose levels were restored towards normal. CONCLUSION: It is concluded that oral magnesium administration given at the time of diabetes induction may be able to restore thermal hyperalgesia, magnesium deficiency and hyperglycemia and in diabetic rats.


Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Hiperalgesia/prevención & control , Sulfato de Magnesio/uso terapéutico , Administración Oral , Animales , Glucemia/efectos de los fármacos , Neuropatías Diabéticas/prevención & control , Calor/efectos adversos , Magnesio/sangre , Sulfato de Magnesio/administración & dosificación , Masculino , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA